Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenanthroline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | CCR1 | P32246 | 3/20 | 0.67 |
| ▸ | CCR5 | P51681 | 3/20 | 0.67 |
| ▸ | CCR8 | P51685 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | MMP2 | P08253 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MMP8 | P22894 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL623252 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL8722750 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL29278209 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL30613730 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL8686399 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL2210775 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL6045190 | 0.94 | KDM4E (0.70) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL11867003 | 0.83 | KDM4E (0.73) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL1893812 | 0.83 | KDM4E (0.73) | KDM4ELMNAMAPTTDP1HTT | |
| Phenanthroline SCHEMBL31562164 | 0.83 | KDM4E (0.73) | KDM4ELMNAMAPTTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091351-B2 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060106006-A1 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-05-18 | — | — | US | disclosed |
| US-20040235815-A1 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235815-A1 | Vanadium compounds for treating cancer | VHL, TP53, VAV1 | KDM4E 577/4885LMNA 3932/4885MAPT 4661/4885 |
| US-20060106006-A1 | Vanadium compounds for treating cancer | VHL, TP53, VAV1 | KDM4E 577/4885LMNA 3932/4885MAPT 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.